(TRVI) Trevi Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.016m USD | Total Return: 114.5% in 12m
Industry Rotation: -12.2
Avg Turnover: 18.6M
Warnings
Share dilution 23.7% YoY
High Debt while negative Cash Flow
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
Leader
Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical firm focused on developing Haduvio, an oral extended-release formulation of nalbuphine. The company primarily targets chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough, with lead candidates currently in Phase 2 clinical trials. Headquartered in New Haven, Connecticut, the company operates under a licensing agreement with Keenova Therapeutics plc for the commercialization of nalbuphine hydrochloride formulations.
The clinical-stage biotech sector is characterized by high research and development costs and a heavy reliance on successful Phase 2 and Phase 3 trial outcomes to secure regulatory approval. Trevi’s business model centers on the proprietary application of nalbuphine, a dual opioid agonist-antagonist, to address neurological pathways involved in chronic cough and pruritus. For a deeper look into the companys valuation metrics, consider reviewing the data on ValueRay. This niche focus on respiratory and neurological symptoms allows the company to target orphan drug designations or underserved patient populations within the broader pharmaceutical market.
- Phase 2b clinical data for Haduvio in IPF chronic cough drives valuation
- Regulatory approval path for refractory chronic cough determines long-term market entry
- Clinical trial enrollment timelines and R&D spending impact cash runway exhaustion
- License agreement with Keenova Therapeutics influences international commercialization and royalty potential
- Success of nalbuphine ER formulation determines competitive positioning in niche respiratory markets
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 20.82 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -45.3m > Net Income -45.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.6m) vs 12m ago 23.79% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.14%; Δ -0.14% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 176.1m - Total Current Liabilities 7.12m) / Total Assets 179.6m |
| B: -1.91 (Retained Earnings -343.0m / Total Assets 179.6m) |
| C: -0.33 (EBIT TTM -47.4m / Avg Total Assets 143.3m) |
| D: -45.87 (Book Value of Equity -343.1m / Total Liabilities 7.48m) |
| Altman-Z'' Score: -50.44 = D |
Over the past week, the price has changed by -9.10%, over one month by -9.87%, over three months by +30.45% and over the past year by +114.53%.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.5 | 68.9% |
Revenue TTM = 0.0 USD
EBIT TTM = -47.4m USD
EBITDA TTM = -47.3m USD
Long Term Debt = 753k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 318k USD (from shortTermDebt, last quarter)
Debt = 1.07m USD (corrected: LT Debt 753k + ST Debt 318k)
Net Debt = -170.7m USD (recalculated: Debt 1.07m - CCE 171.8m)
Enterprise Value = 1.85b USD (2.02b + Debt 1.07m - CCE 171.8m)
Interest Coverage Ratio = unknown (Ebit TTM -47.4m / Interest Expense TTM 0.0)
EV/FCF = -57.78x (Enterprise Value 1.85b / FCF TTM -31.9m)
FCF Yield = -1.73% (FCF TTM -31.9m / Enterprise Value 1.85b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 103k) / Revenue TTM)
Tobins Q-Ratio = 10.27 (Enterprise Value 1.85b / Total Assets 179.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.07m)
Taxrate = 21.0% (US default 21%)
NOPAT = -37.5m (EBIT -47.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 24.75 (Total Current Assets 176.1m / Total Current Liabilities 7.12m)
Debt / Equity = 0.01 (Debt 1.07m / totalStockholderEquity, last quarter 172.1m)
Debt / EBITDA = 3.61 (negative EBITDA) (Net Debt -170.7m / EBITDA -47.3m)
Debt / FCF = 5.35 (negative FCF - burning cash) (Net Debt -170.7m / FCF TTM -31.9m)
Total Stockholder Equity = 185.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.83% (Net Income -45.6m / Total Assets 179.6m)
RoE = -24.53% (Net Income TTM -45.6m / Total Stockholder Equity 185.9m)
RoCE = -25.40% (EBIT -47.4m / Capital Employed (Equity 185.9m + L.T.Debt 753k))
RoIC = -19.66% (negative operating profit) (NOPAT -37.5m / Invested Capital 190.5m)
WACC = 5.85% (E(2.02b)/V(2.02b) * Re(5.85%) + D(1.07m)/V(2.02b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 94.39 | Cagr: 18.85%
[DCF] Fair Price = unknown (Cash Flow -31.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.90 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.10 | Chg30d=-4.08% | Revisions=+14% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=-1.67% | Revisions=+25% | Analysts=10
EPS current Year (2026-12-31): EPS=-0.45 | Chg30d=-4.42% | Revisions=+25% | GrowthEPS=-40.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.52 | Chg30d=+7.61% | Revisions=+43% | GrowthEPS=-16.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +43%